Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin + Irinotecan + Cetuximab as first-line therapy in advanced or metastatic gastric cancer
2006-001989-16Phase 2Completed
- Sponsor
- AGMT
- Start
- Nov 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, oxaliplatin and irinotecan in gastric cancer (GC), sponsored by AGMT. Primary endpoint: Objective response rate by RECIST. Started Nov 2006; status: completed.
02
Drugs
cetuximaboxaliplatinirinotecan
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2006-001989-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001989-16.